Home » Newsletters » BioWorld Science

BioWorld Science

May 11, 2005

View Archived Issues

Phase III efficacy results for Oravescent in breakthrough cancer pain

VaxGen and EndoBiologics to pursue research of meningitis B vaccine

Genzyme to acquire Bone Care International

Novartis profiles Q1 developments

Y-39983 reduces intraocular pressure in preclinical studies

Low doses of AdPEDF.11D inhibit choroidal neovascularization

Preclinical evidence for Enhanze SC as a therapy for complications of cataract surgery

New data on thymosin beta4 as an ophthalmologic therapy

Efficacy of targeted cytotoxic-LHRH analogues for endometrial cancer / News in Context

Approval letter for Biovail's Tramadol ODT

NeoRx discontinues STR, expedites picoplatin development

RhuDex enters phase I

Viragen licenses anti-CD55 antibody from Cancer Research Technology

Peginterferon alfa-2b plus ribavirin reported safe and effective in HCV-infected children

ASCL-002 reduces atherogenesis by inhibiting monocyte recruitment

A dendritic cell vaccine induces CEA-specific immune responses in cancer patients

Motexafin reported to disrupt zinc metabolism in cancer cells

Tefibazumab shows promise as adjunct therapy for S. aureus bloodstream infections

Clinical trials show ranibizumab is effective in AMD

Tacrolimus to be evaluated in the treatment of hand dermatitis

Korea Research Institute of Chemical Technology imparts new antifungal agents

New targets and treatments for cardiovascular disorders reported

Recent patents cover new agents for depression, anxiety, psychosis, etc.

Denufosol tetrasodium well tolerated in cystic fibrosis patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...